Stable disease is not preferentially observed with targeted therapies and as currently defined has limited value in drug development

Cancer Journal

Volumn 15, Issue 5, 2009, Pages 366-373

  Vidaurre, Tatiana ^a   Wilkerson, Julia ^a   Simon, Richard ^a   Bates, Susan E ^a   Fojo, Tito ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer therapy; Clinical trials; Complete response rate; Cytotoxic therapies; Drug assessment; Drug evaluation; Overall response rate; Partial response rate; Phase II studies; Progression free survival; RECIST; Stable disease; Targeted therapies; WHO criteria

Indexed keywords

AMRUBICIN; ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; BEXAROTENE; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; ESTRAMUSTINE; ETOPOSIDE; FLUOROURACIL; GEFITINIB; GEMCITABINE; IFOSFAMIDE; IMATINIB; IRINOTECAN; IXABEPILONE; LAPATINIB; LENALIDOMIDE; MIDOSTAURIN; SORAFENIB; SUNITINIB; THALIDOMIDE; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL RESEARCH; DRUG ACTIVITY; DRUG RESEARCH; DRUG TARGETING; HISTOPATHOLOGY; HUMAN; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MEDICAL LITERATURE; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE;

CLINICAL TRIALS, PHASE II AS TOPIC; CYTOTOXINS; DISEASE-FREE SURVIVAL; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 70350135946     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e3181b9d37b     Document Type: Review

References (26)

1. Gelmon KA, Eisenhauer EA, Harris AL, et al. Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? J Natl Cancer Inst. 1999;91:1281-1287.
2. Korn EL, Arbuck SG, Pluda JM, et al. Clinical trial designs for cytostatic agents: are new approaches needed? J Clin Oncol. 2001;19:265-272.
3. Eisenhauer EA. Phase I and II trials of novel anti-cancer agents: endpoints, efficacy and existentialism. Ann Oncol. 1998;10:1047-1052.
4. Druker BJ, Guilhot F, O'Brien SG, et al; IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408-2417.
5. Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 2008;26:626-632.
6. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-124.
7. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med. 2009;360:563-572.
8. Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 2009;27:672-680.
9. Roberts TG Jr, Lynch TJ Jr, Chabner BA. The phase III trial in the era of targeted therapiesgeted therapy: unraveling the "go or no go" decision. J Clin Oncol. 2003;21:3683-3695.
10. Gasparini G, Longo R, Fanelli M, et al. Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. J Clin Oncol. 2005;23:1295-1311.
11. Soulieres D, Senzer NN, Vokes EE, et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol. 2004;22:77-85.
12. Burris HA III, Hurwitz HI, Dees EC, et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol. 2005;23:5305-5313.
13. Wolf M, Swaisland H, Averbuch S. Development of the novel biologically targeted anticancer agent gefitinib: determining the optimum dose for clinical efficacy. Clin Cancer Res. 2004;10:4607-4613.
14. Brachmann S, Fritsch C, Maira SM, et al. PI3K and mTOR inhibitors: a new generation of targeted anticancer agents. Curr Opin Cell Biol. 2009;21:194-198.
15. Strumberg D, Clark JW, Awada A, et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist. 2007;12:426-437.
16. Stadler WM, Ratain MJ. Development of target-based antineoplastic agents. Invest New Drugs. 2000;18:7-16.
17. Ratain MJ, Stadler WM. Clinical trial designs for cytostatic agents. J Clin Oncol. 2001;19:3154-3155.
18. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
19. Escudier B, Eisen T, Stadler WM, et al; TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125-134.
20. Escudier B, Szczylik C, Hutson TE, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:1280-1289.
21. Cheson BD, Horning SJ, Coiffier B, et al. Report of an International Workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol. 1999;17:1244-1253.
22. Ratain MJ, Eckhardt SG. Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. J Clin Oncol. 2004;22:4442-14425
23. El-Maraghi RH, Eisenhauer EA. Review of phase II trial designs used in studies of molecular targeted therapies: outcomes and predictors of success in phase III. J Clin Oncol. 2008;26:1346-1354.
24. Goffin J, Baral S, Tu D, et al. Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval. Clin Cancer Res. 2005;11:5928-5934.
25. Byrd JC, Lin TS, Dalton JT, et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical effi- cacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood. 2007;109:399-404.
26. Phelps MA, Lin TS, Johnson AJ, et al. Clinical response and pharmacokinetics from a phase I study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood. 2009;113:2637-2645.